<DOC>
	<DOCNO>NCT00878800</DOCNO>
	<brief_summary>Open-label , multicentre , dose-escalation Phase I/II study evaluate safety , efficacy , pharmacodynamics , pharmacokinetics combination PXD101 doxorubicin administer q 3 week patient advance solid tumour . Once Maximum Tolerable Dose establish , total 20-40 patient Soft Tissue Sarcoma may enrol MTD dose level examine efficacy safety specific patient population . The trial stop 2 response see among first 20 patient .</brief_summary>
	<brief_title>A Phase I/II Clinical Trial PXD101 Combination With Doxorubicin Patients With Soft Tissue Sarcomas</brief_title>
	<detailed_description />
	<mesh_term>Sarcoma</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Belinostat</mesh_term>
	<criteria>1 . Signed consent IEC ( Independent Ethics Committee ) approve Information consent form 2 . A . For dose escalation phase : Patients histological cytological confirm solid tumour ( include sarcoma ) , know curative therapy B . For MTD expansion phase : Patients establish diagnosis soft tissue sarcoma need first line chemotherapy measurable disease 3 . Performance status ( ECOG ) ≤ 2 4 . Life expectancy least 3 month 5 . Age ≥ 18 year 6 . Acceptable liver , renal bone marrow function include follow : 1 . Bilirubin ≤ 1.5 time upper limit normal ( ULN ) 2 . AST ( [ Aspartate Amino Transferase ] ] ( SGOT ) , ALT ( SGPT ) Alkaline Phosphatase ≤ 3 time upper limit normal ( liver metastasis present , ≤ 5 x ULN allow ) 3 . Serum creatinine ≤ 1.5 time upper limit normal ( ULN ) 4 . Leucocytes &gt; 2.5 x 109/ L , neutrophils &gt; 1.0 x 109/L , platelet &gt; 100 x 109/L 5 . Haemoglobin &gt; 9.0 g/dL &gt; 5.6 mmol/l 7 . Acceptable coagulation status : PT APTT ( [ activate partial thromboplastin time ] ) within ≤ 1.5 time upper limit normal therapeutic range anticoagulation . 8 . A negative pregnancy test woman childbearing potential . For men woman child produce potential , use effective contraceptive method study require 9 . Serum potassium within normal range 1 . Treatment investigational agent within last 4 week 2 . Prior anticancer therapy , within last 3 week trial dose include chemotherapy , radiotherapy , endocrine therapy immunotherapy 3 . Coexisting active infection coexist medical condition likely interfere trial procedure , include significant cardiovascular disease ( New York Heart Association Class III IV cardiac disease , myocardial infarction within past 6 month , unstable angina , congestive heart failure require therapy , unstable arrhythmia need antiarrhythmic therapy , evidence ischemia ECG , mark baseline prolongation QT/QTc ( [ correct QT interval ] ) interval , e.g. , repeat demonstration QTc interval &gt; 500 msec ; Long QT Syndrome ; require use concomitant medication PXD101 infusion day may cause Torsade de Pointes . 4 . Altered mental status preclude understand informed consent process and/or completion necessary study 5 . Concurrent second malignancy 6 . History hypersensitivity doxorubicin 7 . A . For dose escalation phase : More two prior dos anthracycline , three prior line chemotherapy give metastatic disease B . For MTD expansion phase : Prior chemotherapy 8 . Bowel obstruction impend bowel obstruction 9 . Known HIV positivity 10 . LVEF ( [ leave ventricular ejection fraction ] ) normal range ( 45 % MUGA ) 11 . Presence metastatic disease , opinion investigator , would require palliative treatment within 4 week enrolment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2015</verification_date>
	<keyword>Phase I/II trial</keyword>
	<keyword>Solid tumor</keyword>
	<keyword>Soft tissue sarcoma</keyword>
	<keyword>PXD101</keyword>
	<keyword>Doxorubicin</keyword>
</DOC>